Michael A. Singer, MD - Bringing Clarity to Patient Management in Diabetic Retinopathy and Diabetic Macular Edema: Practical Strategies to Integrate VEGF-Targeted Agents

Please visit answersincme.com/QND860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in ophthalmology discusses integrating anti–vascular endothelial growth factor (anti-VEGF) agents into treatment strategies for diabetic retinopathy (DR) and diabetic macular edema (DME). Upon completion of this activity, participants should be better able to: Review the clinical impact of approved VEGF-targeted agents for the treatment of DR and DME; Describe guideline-concordant, evidence-based strategies to select appropriate therapy for patients with DR with or without DME; and Outline patient-centered management approaches to enhance outcomes for patients with DR with or without DME receiving VEGF-targeted therapy.

There are no comments yet.

Please log in to write the first comment.